Although the finding was not statistically significant, patients with HR-positive ductal histologic disease had numerically better outcomes in the low ERBB2 expression group compared with the no ERBB2 expression group (eFigure 1A and B and eFigure 3A and B in Supplement 1), whereas patients with lobular histologic disease had numerically better outcomes in the no ERBB2 expression group compared with the low ERBB2 expression group (eFigure 2A and B and eFigure 4A and B in Supplement 1). The gene discussed is ERBB2; the disease is glycogen storage disease VI.